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Background: Despite substantive growth in utilization of positron emission tomography (PET) myocardial
perfusion imaging (MPI), evidence on its prognostic value is limited. We aimed to comprehensively evaluate
the prognostic literature of PET perfusion measures according to the most recent American Heart Association
recommendations for assessment of novel cardiovascular biomarkers.
Methods: We searched the literature for studies reporting associations of PET MPI measures and outcomes in
patients with known or suspected coronary artery disease. We documented hazard ratios (HR) and 95%
conﬁdence intervals (CI) of association effects and quantitatively synthesized them with random-effects meta-
analyses. Discrimination, calibration and risk reclassiﬁcation after addition of PET MPI measures to standard
prognostic models were documented.
Results:We identiﬁed 20 eligible studieswithmedian n=551 patients. Inmeta-analyses, the extents of ischemic
and scarred myocardium were signiﬁcantly associated with cardiac death. Meta-analyses of multivariate
estimates for abnormal summed stress score ≥4 and myocardial perfusion reserve b2 revealed signiﬁcant
associations with major adverse cardiovascular events [HR (95% CI) 2.30 (1.53–3.44) and 2.11 (1.33–3.36),
respectively]. Changes in model discrimination, calibration or risk reclassiﬁcation were reported in 5 studies
(8 prognostic evaluations). There were marginal improvements in discrimination based on C index and no
improvements in model calibration. Net reclassiﬁcation index ranged from 9.8% to 14.2% and risk classiﬁcation
was signiﬁcantly improved in 4/5 prognostic evaluations.
Conclusions: PET MPI measures were strongly associated with adverse patient outcomes. Risk classiﬁcation was
more consistently improved than discrimination and calibration after addition of PET MPI measures, but
reporting of such metrics was overall limited.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Positron emission tomography (PET) myocardial perfusion imaging
(MPI) has emerged as an important tool in the evaluation of coronary
artery disease (CAD). PETMPI offers an accurate assessment of myocar-
dial perfusion with favorable diagnostic characteristics and is increas-
ingly utilized. In a recent meta-analysis of 166 articles of different MPI
methods, PET achieved the highest diagnostic performance, over both
single-photon emission tomography (SPECT) and cardiac magnetic
resonance imaging, with a pooled sensitivity of 84% and speciﬁcity
81% [1].Diseases, Mayo Clinic, 200 First
u (P. Chareonthaitawee).
land Ltd. This is an open access articleBeyond diagnostic performance, there is accumulating data on
the prognostic signiﬁcance of PET perfusion abnormalities with regard
to patient outcomes [2–4]. Most studies have focused on associations
between MPI measures and outcomes but statistical association,
even though a fundamental condition, is insufﬁcient to establish
a marker's role in clinical decision-making. A clinically useful bio-
marker should essentially offer incremental predictive information
beyond well-established risk factors and improve risk stratiﬁcation
with the ultimate goal of altering patient management and outcomes
[5–7].
In the present study we aim to map the current evidence on the
prognostic value of PET MPI measures in patients with known or
suspected CAD.We aim to assess the statistical signiﬁcance and strength
of associations with patient outcomes, and comprehensively evaluate
the predictive value of PET perfusion measures according to the
most recent American Heart Association (AHA) recommendations forunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ination ability, model calibration, and risk reclassiﬁcation [5,8–10].
2. Methods
2.1. Literature search and study eligibility
We searchedMEDLINE, EMBASE, and CENTRAL using the terms pos-
itron emission tomography, myocard*, perfusion, and (prognos* OR pre-
dict*) for eligible studies without year restriction. We limited the
search to English language studies in humans. Latest update search
was performed on April 25, 2014. We also searched abstracts and pre-
sentations of the most recent major cardiology meetings and the
clinicaltrials.gov registry for yet unpublished studies. Finally, we perused
the reference lists of all eligible articles for any additional studies not
identiﬁed with the above searches.
All studies were assessed for eligibility at the title and abstract level
and potentially eligible ones were assessed in full text. We included
prospective and retrospective studies in patients with known or
suspected CAD reporting on associations of any PET MPI measure with
clinical outcomes during follow-up. Such measures include summed
stress score (SSS), summed rest score (SRS), summed difference score
(SDS), myocardial blood ﬂow (MBF), myocardial perfusion reserve
(MPR), extent of abnormal, ischemic or scarred myocardium, and tran-
sient ischemic dilatation (TID) ratio.We acknowledged that theremight
exist subtle variations in techniques for acquisition of these measures
but adhered to the deﬁnition provided in each study. We only focused
on perfusion measures and did not consider left ventricular ejection
fraction reserve among the measures of interest. We excluded studies
focusing on diagnostic performancewithout outcome reporting; studies
assessing the prognostic value of tracer uptake or perfusion-uptake
mismatch measures; those evaluating prognostic factors in patients
with normal PET MPI scans; studies on perfusion changes in response
to cold pressor testing; studies reporting non-clinical outcomes
(e.g. changes in echocardiographic measures); and studies in patients
with non-ischemic cardiomyopathy. When two different studies on
the same patient cohort were identiﬁed, we included the study with
the longest follow-up. Literature search and study selection were
performed by two investigators who reached consensus in case of
discrepancies.
2.2. Data extraction and measures of prognostic value
We recorded information on imaging technique, patient enrollment
period, demographics, follow-up duration, and type and number of
clinical events. Outcomes of interest included all-cause death, cardiac
death, myocardial infarction (MI) and the composite of major adverse
cardiovascular events (MACE) as deﬁned by each study. We extracted
risk estimates with 95% conﬁdence intervals (CI) and p-values for asso-
ciations between MPI measures and the outcomes of interest. When
both univariate and multivariate risk estimates were presented, we
included only the latter, and among the multiple multivariate models
in the same study, we kept the one with the larger number of adjusting
variables. When effect estimates were not available, we documented
the p-values derived from survival comparisons in different perfusion
categories.
Furthermore, in order to assess how the predictive ability of models
consisting of standard clinical or imaging variables improved with the
addition of PETMPImeasureswe documented information on statistical
measures proposed by the AHA for the evaluation of novel markers of
cardiovascular risk [5]. These included discrimination ability, model
calibration, and risk reclassiﬁcation. Discrimination ability indicates
how well a model differentiates those who will suffer an event from
those who will not. We documented the C index and other discrimina-
tion metrics (D statistic, R2 statistic, Brier score, when available) after
the addition of the PETMPImeasures [9,11]. Model calibration indicateshow well predicted and observed risks correlate. It is quantiﬁed
with goodness-of-ﬁt statistics such as Hosmer–Lemeshow and Nam–
D'Agostino [10] and we documented how these changed with the
addition of PET MPI measures to the standard baseline prognostic
model. Finally, a new biomarker should ideally reclassify patients in
more appropriate risk categories. We documented percentages of
patients correctly reclassiﬁed (upwards or downwards) and, when
available, the net reclassiﬁcation index (NRI), which indicates the net
number of patients reclassiﬁed to the correct risk category [8,12].
2.3. Statistical analysis
We report categorical variables as frequencies and percentages and
continuous variables asmeans and standard deviations (SD) ormedians
and interquartile ranges (IQR). Effect size estimates of associations
between the PET MPI measures and patient outcomes were pooled
in meta-analyses per perfusion measure using DerSimonian–Laird
random-effects models for cardiac death and MACE [13]. Estimates
derived from univariate analyses were pooled separately from those of
the multivariate analyses. Special consideration was made not to
include results of studies with potentially overlapping populations in
the samemeta-analysis. Heterogeneity was assessed with the Cochrane
Q statistic based on chi-square testing (statistically signiﬁcant when
p-value b 0.10). Its magnitude was quantiﬁed with the I2 statistic (on
a scale of 0–100%, with values N50% indicating large heterogeneity)
[14]. Analyses were conducted using Stata 12.0 software (StataCorp,
College Station, TX, USA). P-values are two-tailed.
3. Results
3.1. Literature search
The literature search yielded a total of 620 studies that were
assessed in the title and/or abstract level and 37 potentially eligible
studies were assessed in full-text. Seventeen studies were deemed
eligible after the exclusion of studiesmainly because of lack of reporting
of patient outcomes (n = 12). Another 8 studies were excluded for
other reasons as shown in Fig. 1. Three additional eligible studies were
identiﬁed by scrutinizing references of the eligible studies. One poten-
tially eligible study with suspended participant recruitment and with-
out any published results available was identiﬁed in clinicaltrials.gov.
Thus, 20 studies were ﬁnally eligible. One of the included studies [15]
reported on a multicenter registry and partially overlapped with 4 of
the other included studies [16–19]. Partial overlap potentially also
existed between different single-center studies from the same institu-
tion focusing on different perfusion metrics or patient subgroups.
3.2. Study characteristics
Studies were published over a span of 20 years (1993–2013) and 7
were prospective. Most studies (n= 15) used 82Rb as a perfusion tracer
and the rest utilized 13N-ammonia or both. One study speciﬁcally
evaluated patients with chronic kidney disease [20]. The median
number of included patients was 551 (IQR 232–1291). The mean or
median follow-up for clinical outcomes ranged from 1 to 7.3 years.
Further details on the study characteristics are shown in Table 1.
3.3. Evaluated outcomes and strength of prognostic associations
Semiquantitative measures showed a variable association with
adverse outcomes (Supplementary Table 1). In the recent study by
Fahrad et al., SDS, SSS, and SRS were all signiﬁcantly associated with
MACE in univariate analyses but only SDS remained signiﬁcant in the
multivariate analysis [21]. Fixed and reversible defects were strong
predictors of adverse outcomes in the multivariate analyses in the
studies by Fiechter et al. [22], Fukushima et al. [4], Herzog et al. [23],
Fig. 1. Flowchart of study selection.
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Ziadi et al. [18]. In quantitative perfusion analysis, impaired MBF and
MFR were associated with MACE in all studies [3,4,18,21,23,27,28].
Cardiac death was one of the evaluated outcomes in 8 studies with
a median number of 85 events (IQR 37–161) and associations with
several different perfusion measures were reported. In the largest
study by Dorbala et al. [15], a 10-unit increase in the percentage of
ischemic myocardium was associated with a 70% increased risk for
cardiac death in univariate analysis and 34% increased risk in multivar-
iate analysis. This was concordant to the effect observed in the Murthy
et al. study (univariate HR 1.58, p b 0.001, for cardiac mortality) [3].
The SDS was also signiﬁcantly predictive of hard cardiac events in two
studies [21,29]. SSS ≥4 predicted cardiac death or MI and other MACE
in three studies [4,23,24] but not in Ziadi et al. [18]. It also failed to pre-
dict all-cause mortality in the study by Rischpler et al. [30]. Age- and
sex-adjusted proportional hazards analysis suggested a 4-fold increased
risk for cardiac death per 1-SD decrease of MFR in the Tio et al. study
[28] and MPR b2 was associated with nearly 3-fold increased risk of
cardiac death in Herzog et al. [23]. Finally, TID was reported in one
study only and a ratio of N1.13 did not predict all-cause mortality [30].
3.4. Meta-analyses of prognostic effect estimates
Five studies reported non-overlapping data that were suitable for
inclusion in the meta-analyses. The results from the Dorbala et al.
study published in 2013 [15] were not included in the same analyses
with the results from four other studies [16–19] due to partial overlap
of patient populations. In the meta-analyses of univariate estimates,
10% increases in ischemic and scarred myocardium were associated
with signiﬁcant increases in cardiac death risk (summary HR 1.66, 95%
CI 1.51–1.82, and HR 1.83, 1.70–1.96, respectively) (Fig. 2). Abnormal
SSS and MPR were also strongly associated with MACE based onestimates from the multivariate analyses with HR (95% CI) 2.30 (1.53–
3.44) and 2.11 (1.33–3.36), respectively. There was no signiﬁcant het-
erogeneity in any of the meta-analyses (all Cochran Q p-values N 0.05
and I2 b 50%).3.5. Discrimination, calibration and risk classiﬁcation
Five studies reported changes in ≥1 additional metric of prognostic
value (discrimination, calibration, or risk classiﬁcation) after inclusion
of PET MPI measures to models including clinical and/or echocardio-
graphic variables in a total of 8 prognostic evaluations (Table 2).
Discrimination ability (based on the C index) for cardiac death
and/or non-fatal MI improved in all 4 studies that evaluated the addi-
tion of the percentage of abnormal myocardium to baseline models
but the improvement was statistically signiﬁcant only in the study by
Dorbala et al. in 2009 [17]. Abnormal MPR signiﬁcantly improved the
discrimination for cardiac mortality only in one study [3]. Hosmer–
LemeshoworNam–D'Agostino chi-square statistics ofmodel calibration
for cardiac mortality did not improve signiﬁcantly with the inclusion of
any MPI measure. Finally, information on risk reclassiﬁcation was
reported in 4 studies. In Dorbala et al. in 2013 [15] there was a signiﬁ-
cant improvement in risk classiﬁcationwith the addition of the percent-
age of abnormal myocardium as net 11.6% of patients were reclassiﬁed
to correct annual cardiac death risk categories. The inclusion of MPR in
models already including a semiquantitativeMPI measure also resulted
in a signiﬁcantly improved cardiac death risk classiﬁcation in the
studies by Murthy et al. (NRI 14.2% and 9.8%) [3,20]. In contrast, MPR
did not have a signiﬁcant risk reclassiﬁcation effect for cardiac death
when added to a model including SSS in the study by Ziadi et al. (p =
0.092) [18]. NRI was marginally statistically signiﬁcant for MACE in
the same study (p = 0.048).
Table 1
Eligible studies evaluating the prognostic value of PET MPI measures with regard to patient outcomes.
Study Radionuclide Study type N patients (male) Age, years Follow-up, years Outcomes (N events) Perfusion measure
Farhad 2013 [21] 82Rb Prospective 335 (139) 64 ± 11
(no MACE)
Median 1.7
(IQR 1.5–1.9)
MACE (35) SSS, SDS, SRS, stress MBF, MPR
Dorbala 2013 [15] 82Rb Retrospective 7061 (3715) 63 ± 13 Median 2.2
(IQR 1.3–3.3)
Cardiac death (169), death
(570)
% myocardium abnormal, scarred,
or ischemic
Rischpler 2012 [30] 82Rb Retrospective 265 (99) 49 ± 9 2.7 ± 0.9 Death (34) SSS, MPR, TID ratio
Williams 2012 [19] 82Rb Retrospective 3739 (1982) 62 ± 13 5.2 ± 1.7 Cardiac death (187), death
(510)
% myocardium abnormal
Murthy 2012 [20] 82Rb Retrospective 866 (435) Median 71
(IQR 61–80)
Median 1.28
(IQR 0.64–2.34)
Cardiac death (88), death
(155)
% myocardium abnormal, MPR
Fiechter 2013 [22] 13N-ammonia Retrospective 621 (484) 60 ± 12 5.7 ± 2.5 Cardiac death or non-fatal MI
(135), MACE (275)
Normal vs abnormal perfusion
(semiquantitative scoring)
Fukushima 2011 [4] 82Rb Retrospective 224 (86) 58 ± 13 1 ± 0.8 MACE (33) SSS, stress MBF, MPR
Ziadi 2011 [18] 82Rb Prospective 677 (430) 64 ± 12 Median 1.1
(IQR 1–1.14)
Cardiac death or MI (27),
MACE (71)
SSS, MPR
Murthy 2011 [3] 82Rb Retrospective 2783 (1333) Median 65
(IQR 56–75)
Median 1.4
(IQR 0.7–3.2)
Cardiac death (137) MPR
Slart 2011 [27] 13N-ammonia Retrospective 119 (96) 67 ± 11 Median 7.3
(IQR NA)
Cardiac death (22), MACE (35) MPR
Tio 2009 [28] 13N-ammonia Prospective 480 (271) 66 ± 11 Median 7.1 MACE (NA), cardiac death (60) MPR
Herzog 2009 [23] 13N-ammonia Retrospective 256 (69) 60 ± 12 5.4 ± 2.2 MACE (78), cardiac death (29) SSS, MPR
Dorbala 2009 [17] 82Rb Retrospective 1432 (675) 63 ± NA 1.7 ± 0.7 MACE (83), death (140) % myocardium abnormal, scarred,
or ischemic based on SSS, SRS, or
SDS, respectively
Chow 2009 [24] 13N-ammonia
or 82Rb
Prospective 124 (77) 62 ± 11
(abnormal PET)
2.3 ± 1.6 Cardiac death or non-fatal MI
(5), MACE (16)
SSS
Lertsburapa 2008 [37] 82Rb Retrospective 1441 (602) 69 ± 12 (alive) 2.7 ± 0.8 Death (132) SSS
Schenker 2008 [29] 82Rb Retrospective 621 (249) 61 ± 13 1.4 ± 0.6 Death or MI (55) SDS
Yoshinaga 2006 [16] 82Rb Prospective 367 (168) 59 ± 11 3.1 ± 0.9 MACE (17), total cardiac
events (59)
SSS
Marwick 1997 [26] 82Rb Prospective 685 (486) 62 ± 11 3.4 ± NA MACE (151), cardiac death
(81)
Summed score defects (rest and
stress) categories: none, small,
moderate, extensive
Marwick 1995 [25] 82Rb Retrospective 72 (48) 67 ± 11 1.5 ± 1 Perioperative (14) and late
(7) cardiac events
Rest and stress perfusion defect
(sensitivity, PPV for adverse
outcome)
Yoshida 1993 [38] 82Rb Prospective 35 (22) 54 ± NA 3 ± 0.3 Death (7) Infarct size ≥23% myocardium
Abbreviations: CAD, coronary artery disease; CKD, chronic kidney disease; MACE, major adverse cardiovascular events (deﬁnition varies across studies); MBF, myocardial blood ﬂow;MI,
myocardial infarction; MPR, myocardial perfusion reserve; NA, not available; PPV, positive predictive value; SDS, summed difference score; SSS, summed stress score; SRS, summed rest
score; and TID, transient ischemic dilation;
“Age” and “follow-up” data are shown as mean ± standard deviation unless otherwise speciﬁed.
57K.C. Siontis, P. Chareonthaitawee / IJC Heart & Vasculature 6 (2015) 54–594. Discussion
We identiﬁed 20 studies that cumulatively provide strong evidence
on associations between myocardial perfusion abnormalities and
adverse outcomes in patients with known or suspected CAD. In the
meta-analyses of studies with available data, 10% increases in ischemic
and scarred myocardium conferred signiﬁcantly increased risks of
cardiac death. Abnormal SSS and reducedMPRwere strongly associated
with MACE in pooled analyses of univariate risk estimates. Beyond
statistical signiﬁcance, reporting of discrimination, calibration and risk
reclassiﬁcation metrics was infrequent. The addition of the percentage
of abnormal myocardium or MPR to models including standard risk
variables did not improvemodel calibration and therewas onlymargin-
al or no improvement in discrimination ability. The PET MPI measures
reclassiﬁed a net of 10–15% of patients to more appropriate risk
categories.
The cardiovascular prognostic research agenda has been enriched in
recent years withmetrics assessing the impact of biomarkers on clinical
decisionmaking and outcomes rather than statistical associations alone
[5,31]. Statistical signiﬁcance and magnitude of association between a
biomarker and an outcome are essential but only suggestive of a
biomarker's ultimate clinical value. In addition, the performance of a
prognostic model does not necessarily improve with the incorporation
of a biomarker that can predict outcomes when studied independently.
A paradigm shift has occurred with the more widespread use of the C
index change that quantiﬁes the ability to better discriminate patients
who will suffer adverse outcomes from those who will not, and
calibration measures which indicate the agreement between predictedand observed risks. It can be argued, however, that risk reclassiﬁcation
may have the greatest clinical implications [8]. Frequently, clinical deci-
sions are made on the basis of the perceived risk for adverse outcome
and management dilemmas tend to be more complex in intermediate
risk patients. Thus, a clinically useful marker should have a signiﬁcant
effect on the reclassiﬁcation of patients across all risk categories, but
most importantly intermediate-risk patients. In the current body of
the PET MPI literature, information on discrimination and calibration
was limited and argues against consistent improvements in either of
these measures. Nevertheless, net reclassiﬁcation was positive in all
studies where this was reported which suggests that PET MPI measures
can have a role in clinical decision making.
Statistical signiﬁcance, magnitude of associations, improvements
in discrimination, calibration, and risk classiﬁcation should qualify a
marker for further evaluation, ideally in randomized controlled trials.
The ultimate evidence on clinical utility of a diagnostic test stems from
its ability to improve outcomes when its result help determine further
diagnostic and therapeutic decisions. Unfortunately, diagnostic
randomized clinical trials are rather sparse in clinical medicine and
tests that reach such level of scrutiny are often shown to have minimal
or no effect on patient outcomes [32]. In a trial evaluating patient
outcomes with F-18-ﬂuorodeoxyglucose PET imaging, patients with
severe left ventricular dysfunction and known or suspected CAD
were randomized to PET-guided management vs. standard care. After
1 year of follow-up, there was no difference in the composite MACE
outcome between the two arms, but there was a signiﬁcant beneﬁt in
the group of patients that adhered to revascularization recommenda-
tions based on the PET ﬁndings [33]. In a post-hoc analysis of the
Fig. 2.Meta-analyses of associations of PET MPI measures with patient outcomes. Effect estimates are derived from multivariate analyses unless marked with * in which case estimates
are derived from univariate analyses. Abbreviations: CD, cardiac death; CI, conﬁdence interval; HR, hazard ratio; MACE, major adverse cardiovascular events; MPR, myocardial perfusion
reserve; and SSS, summed stress score.
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center, there were signiﬁcantly better outcomes with PET-guided man-
agement [34], while another analysis also showed improvement in
quality of life [35]. In another trial, patients with CAD considered for re-
vascularization underwent randomized evaluation with PET vs SPECT
MPI with no difference in patient management or outcomes between
the two arms [36].Table 2
Changes in discrimination, calibration and risk classiﬁcation after the inclusion of PET MPI mea
Study N patients Outcome (N events) Prognostic model
Dorbala 2013 [15] 7061 Cardiac death (169) Clinical covariates†, history of
aspirin, beta-blockers, rest hea
Murthy 2012 [20] 866 Cardiac death (88) Duke clinical score, early revas
eGFR, rest LVEF
Duke clinical score, early revas
eGFR,
rest LVEF, % myocardium abno
reserve
Murthy 2011 [3] 2783 Cardiac death (137) Clinical covariates‡, early reva
rest LVEF
Clinical covariates‡, early reva
rest LVEF, % myocardium abno
reserve
Ziadi 2011 [18] 677 Cardiac death or MI (27) SSS, history of MI, stress LVEF
MACE (71) SSS, demographic factors, CCS
diabetes, stress LVEF
Dorbala 2009 [17] 1432 Cardiac death or MI (83) Clinical covariates, rest LVEF
Abbreviations: CABG, coronary artery bypass graft; CCS, Canadian Cardiovascular Society; CI, co
fraction; MACE, major adverse cardiovascular events; MI, myocardial infarction; MPR, myocard
⁎ p-Value for comparison to C-statistic of model including Duke clinical score and early reva
⁎⁎ p-Value for comparison to C-statistic of model including clinical covariates and early revas
† Age, sex, hypertension, dyslipidemia, diabetes mellitus, history of angina, smoking, BMI.
‡ Age, sex, hypertension, dyslipidemia, diabetes mellitus, family history of coronary artery dOur study has limitations. First, the performance of PETMPI, including
the methods of image analysis and types of radionuclide tracers, was
not standardized among the studies. Second, reporting of perfusion
measures, outcomes and perfusion measure increments for effect
estimates was heterogeneous which prohibited the inclusion of a larger
number of studies in the meta-analyses. Thus, it is difﬁcult to draw
strong conclusions based on these analyses and the results should besures in standard prognostic models.
Perfusion measure(s)
added
Prognostic metrics
PCI or CABG,
rt rate
% myocardium
abnormal
C index change 0.844→ 0.875 (p = 0.05)
NRI 11.6% (95% CI, 2.1%–21%) for annual risk
categories b1%, 1–2.9%, ≥3%
cularization, % myocardium
abnormal
C index (95% CI) 0.75 (0.70–0.81), p = 0.17⁎
Calibration Hosmer–Lemeshow chi-square
change 11.31→ 5.83, p = 0.76
cularization,
rmal, LVEF
MPR C index (95% CI) 0.77 (0.72–0.82), p = 0.17⁎
Calibration Hosmer–Lemeshow chi-square
change 6.92→ 8, p = 0.53
NRI 14.2% (95% CI, 7.6%–21.9%) for annual
risk categories b2%, 2–4%, N4%
scularization, % myocardium
abnormal
C index (95% CI) 0.82 (0.78–0.86), p = 0.17⁎⁎
Calibration Nam–D'Agostino chi-square change
6.2→ 10.3, p = 0.32
scularization,
rmal, LVEF
MPR C index (95% CI) 0.84 (0.80–0.87), p = 0.02⁎⁎
Calibration Nam–D'Agostino chi-square change
9.18→ 10.97, p = 0.28
NRI 9.8% (95% CI, 2.5%–18%) for annual risk
categories b1%, 1–3%, N3%
MPR NRI 11% (p = 0.092) (risk categories NA)
angina class, MPR NRI 11.2% (p = 0.048) (risk categories NA)
% myocardium
abnormal
C index change 0.79→ 0.82, p = 0.04
nﬁdence interval; eGFR, estimated glomerular ﬁltration rate; LVEF, left ventricular ejection
ial perfusion reserve; NA, not available; and NRI, net reclassiﬁcation improvement.
scularization [0.65 (95% CI 0.59–0.71)].
cularization [0.78 (95% CI 0.74–0.82)].
isease, tobacco use, CAD, BMI, chest pain, and dyspnea.
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classiﬁcation measures were rather infrequently reported and meta-
analysis estimates of these metrics were not possible to be derived.
In conclusion, our comprehensive evaluation of the current body of
literature on the prognostic value of PETMPI reveals consistent associa-
tions between abnormal quantitative and semiquantitative perfusion
measures and adverse patient outcomes. There is paucity of evidence
on improvements in discrimination and calibration ability with the in-
clusion of PETMPI measures in prognostic models but limited data sug-
gests that improved risk classiﬁcation may be achieved which can in
turn guide management decisions. The PET MPI research agenda will
beneﬁt from a more standardized reporting of prognostic techniques,
perfusion measures, and outcomes, as well as evaluation of promising
diagnostic strategies in randomized controlled trial settings.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcha.2015.01.005.
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